Jaguar Health Regains Compliance with Nasdaq's Publicly Held Shares Requirement and Receives Additional Extension, Until May 18, 2026, to Demonstrate Compliance with Nasdaq's Bid Price Rule

Jaguar Health (NASDAQ:JAGX) regained compliance with Nasdaq's minimum 500,000 publicly held shares requirement after third-party investors exercised pre-funded warrants on May 4, 2026.

Rhea-AI Summary

Jaguar Health (NASDAQ:JAGX) regained compliance with Nasdaq's minimum 500,000 publicly held shares requirement after third-party investors exercised pre-funded warrants on May 4, 2026.

The Nasdaq Hearings Panel granted an extension of the company's deadline to meet the $1.00 bid price rule to May 18, 2026, during which Jaguar must evidence a closing bid of at least $1.00 for 10 consecutive business days.

Positive

• Public float restored by pre-funded warrant exercises on May 4, 2026
• Nasdaq extension granted through May 18, 2026 to meet bid-price compliance

Negative

• Still non-compliant with the $1.00 bid price rule until 10 consecutive $1.00+ closes are evidenced
• Panel decision reset the bid-price compliance clock, shortening available time to cure

Argus May 8 session

+0.67% close to close Open Argus

Details

News Market Reaction – JAGX

On May 8, the day this news came out, JAGX closed 0.67% above the previous close.

Data tracked by StockTitan Argus for the May 8 session.

Market Context

This announcement confirms Jaguar’s regained compliance with Nasdaq’s 500,000 Publicly Held Shares R...

Analysis

This announcement confirms Jaguar’s regained compliance with Nasdaq’s 500,000 Publicly Held Shares Requirement and a brief extension to May 18, 2026 to satisfy the $1.00 bid price rule for 10 consecutive days. It follows a recent reverse split and prior Panel decisions. Investors may monitor progress toward sustained bid-price compliance, further Nasdaq communications, and any additional use of the company’s effective S-3 shelf or other financing structures disclosed in recent SEC filings.

Key Figures

Publicly Held Shares minimum: 500,000 shares Minimum bid price: $1.00 per share Compliance period: 10 consecutive business days +2 more

Publicly Held Shares minimum

500,000 shares

Nasdaq Listing Rule 5550(a)(4) requirement for continued listing

Minimum bid price

$1.00 per share

Nasdaq Listing Rule 5550(a)(2) bid price rule

Compliance period

10 consecutive business days

Required closing bid price duration under Nasdaq Listing Rule 5810(c)(3)(A)

New bid-rule deadline

May 18, 2026

Extended Panel deadline to demonstrate bid price compliance

Prior bid-rule deadline

May 15, 2026

Original Panel deadline before one-day extension

Historical Context

5 past events · Latest: May 06

5 events

1. May 06

   FDA discussion update

   24h Move

   -6.3%

   Preliminary FDA discussion on Breakthrough Therapy Designation for crofelemer in MVID.

2. May 04

   Product expansion

   24h Move

   -51.4%

   Launch of Neonorm Dog extending the animal health gut-support franchise.

3. Apr 29

   Trial effectiveness data

   24h Move

   -6.6%

   Statistically significant crofelemer trial results for chemotherapy-induced diarrhea in dogs.

4. Apr 27

   Nasdaq extension & split

   24h Move

   -27.8%

   Nasdaq bid-price compliance extension and 1-for-35 reverse stock split announcement.

5. Apr 24

   Conference abstracts

   24h Move

   -1.7%

   Acceptance of late-breaking ESPGHAN abstracts on pediatric intestinal failure treatment.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

publicly held shares, pre-funded warrants, nasdaq hearings panel

3 terms

publicly held shares regulatory

"did not comply with the minimum 500,000 Publicly Held Shares requirement for continued"

Shares that are publicly held are portions of a company that any investor can buy or sell on public markets, like slices of a pie owned by many people rather than a few insiders. They matter because they determine how easy it is to trade the stock, influence company control through voting and can affect price swings and dividend payments as supply and demand change in the market.

pre-funded warrants financial

"exercise on May 4, 2026, by certain third-party investors of existing pre-funded warrants"

Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.

nasdaq hearings panel regulatory

"received a decision letter from the Nasdaq Hearings Panel ("Panel") granting"

A Nasdaq hearings panel is a group of experts that reviews cases when a company's stock listing is at risk of being removed from the exchange. They evaluate whether the company has met certain standards and determine if it can keep trading on Nasdaq. This process matters to investors because it can affect a company's ability to raise money and maintain credibility in the market.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN FRANCISCO, CA / ACCESS Newswire / May 8, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today provided an update on the status of the Company's listing on The Nasdaq Stock Market ("Nasdaq"). On May 6, 2026, Jaguar received a decision letter from the Nasdaq Hearings Panel ("Panel") granting the Company's request for an extension to demonstrate compliance with the Nasdaq Listing Rules.

As previously disclosed, on May 1, 2026, Jaguar received written notification from the staff of the Listing Qualifications Department (the "Staff") of Nasdaq notifying the Company that Jaguar did not comply with the minimum 500,000 Publicly Held Shares requirement for continued inclusion set forth in Nasdaq Listing Rule 5550(a)(4) (the "Publicly Held Shares Requirement"). In addition, Staff noted that under Nasdaq Listing Rule 5810(c)(3)(A), the Company would remain non-compliant with both the minimum $1.00 bid price requirement under Nasdaq Listing Rule 5550(a)(2) (the "Bid Price Rule") and the Publicly Held Shares Requirement until the failure to meet the Publicly Held Shares Requirement is cured and, thereafter, the Company evidences a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days, unless Staff exercises its discretion to extend the 10-day period as discussed in Nasdaq Listing Rule 5810(c)(3)(H).

Following the exercise on May 4, 2026, by certain third-party investors of existing pre-funded warrants to purchase Common Stock, the Company regained compliance with the Publicly Held Shares Requirement.

In its letter, the Panel stated that the Company's non-compliance with Listing Rule 5550(a)(4) reset the clock for the Company to regain compliance with the Bid Price Rule. Based upon the Company's representations, the Panel was willing to grant an additional one-day extension from May 15, 2026 to May 18, 2026 to the Company's deadline to demonstrate compliance with the Bid Price Rule by evidencing a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days.

Forward-Looking Statements

Certain statements in this press release constitute "forward-looking statements." In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to several risks, uncertainties, and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

Contact:

hello@jaguar.health
Jaguar-JAGX

SOURCE: Jaguar Health, Inc.

View the original press release on ACCESS Newswire

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How did Jaguar Health (JAGX) regain compliance with Nasdaq's publicly held shares rule?

Jaguar regained compliance when third-party investors exercised pre-funded warrants on May 4, 2026. According to the company, those exercises increased the number of publicly held shares above Nasdaq's 500,000-share minimum.

What deadline did Nasdaq give Jaguar Health (JAGX) to meet the $1.00 bid price rule?

Nasdaq's Hearings Panel extended Jaguar's deadline to May 18, 2026 to demonstrate compliance. According to the company, Jaguar must show a closing bid of at least $1.00 for 10 consecutive business days.

Does Jaguar Health (JAGX) still need to meet any Nasdaq requirements after regaining public float?

Yes. Jaguar remains required to satisfy the $1.00 bid price rule for 10 consecutive business days. According to the company, the public-float cure does not remove the bid-price requirement.

What does the Nasdaq Panel's 'reset the clock' mean for Jaguar Health (JAGX)?

The Panel's action restarted the period for meeting the bid-price rule, shortening Jaguar's effective cure timeline. According to the company, this required the extension to May 18, 2026 to demonstrate compliance.

What event on May 4, 2026 affected Jaguar Health's (JAGX) Nasdaq status?

On May 4, 2026 certain third-party investors exercised existing pre-funded warrants to buy common stock. According to the company, those exercises resulted in compliance with the publicly held shares requirement.